• Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney Invest Now master your money
Moneycontrol

Home » News » Business

Jan 11, 2017, 12.57 PM | Source: Moneycontrol.com

Daiichi to shut down Indian R&D centre; 170 employees impacted

“Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline,” the company said in a statement.

Like this story, share it with millions of investors on M3

Daiichi to shut down Indian R&D centre; 170 employees impacted

“Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline,” the company said in a statement.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Japanese drug maker Daiichi Sankyo on Wednesday said it has decided to pull down the shutters of its Indian R&D centre in Gurgaon, as part of its global restructuring programme to boost its productivity.

“Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline,” the company said in a statement.

Daiichi presently employs approximately 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation.

Following its closure, Daiichi’s R&D pipeline, including research themes selected by the Global Health Innovative Technology Fund will be transferred to Daiichi Sankyo’s R&D division in Japan, the company said.

Daiichi’s didn’t disclose the fate of the 170 employees.

The shutdown in India follows Daiichi’s closure of UK and Germany R&D sites as the company plans to consolidate its R&D activity to drive down costs.

Daiichi took over Ranbaxy’s R&D division and retained most of its 200 odd scientists as part of its USD 4 billion acquisition of India generic drug maker Ranbaxy in 2008.

The closure of Gurgaon centre marks the end of Daiichi’s direct presence in Indian through the botched-up acquisition of Ranbaxy. Daiichi sold Ranbaxy to Sun Pharma in April 2014 after the US banned four key plants and imposed USD 500 million penalty for falsifying data at its drug facilities and following shoddy manufacturing practices.

Daiichi said it has won an arbitration in Singapore against Ranbaxy’s erstwhile promoters Malvinder Mohan Singh and Shivinder Mohan Singh, that entitles it to Rs 3,500 crore in damages for concealing facts related to Ranbaxy prior to the acquisition.

Singh brothers are contesting the case.

Buy, Hold, Sell ? Hear it first on M3
Daiichi to shut down Indian R&D centre; 170 employees impacted

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login